NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note released on Monday. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Performance

Shares of NeuroMetrix stock opened at $3.81 on Monday. The company’s 50 day moving average price is $4.04 and its two-hundred day moving average price is $3.89. NeuroMetrix has a fifty-two week low of $2.66 and a fifty-two week high of $4.73.

NeuroMetrix (NASDAQ:NURO) last issued its quarterly earnings data on Tuesday, August 6th. The medical device company reported ($0.74) earnings per share for the quarter. NeuroMetrix had a negative return on equity of 41.74% and a negative net margin of 181.04%. The firm had revenue of $0.77 million for the quarter.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.